{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:45:38Z","timestamp":1792003538934,"version":"4.4.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e26479","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T16:03:40Z","timestamp":1708445020000},"page":"e26479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Bridging the gap between statistical significance and clinical relevance: A systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7385-9121","authenticated-orcid":false,"given":"Biswamohan","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pachipala","family":"Sudheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopa","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayush","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M V Padma","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilima","family":"Nilima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3654-8137","authenticated-orcid":false,"given":"Venugopalan Y.","family":"Vishnu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e26479_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2018.08.018","article-title":"Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale","volume":"58","author":"Makkos","year":"2019","journal-title":"Parkinsonism Relat. Disorders"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26479_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jclinepi.2009.03.016","article-title":"A new approach to combining clinical relevance and statistical significance for evaluation of quality of life changes in the individual patient","volume":"63","author":"Kemmler","year":"2010","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26479_bib3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status: Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Contr. Clin. Trials"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26479_bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","article-title":"Understanding the minimum clinically important difference: a review of concepts and methods","volume":"7","author":"Copay","year":"2007","journal-title":"Spine J."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26479_bib5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26479_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12955-020-01344-w","article-title":"How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods","volume":"18","author":"Mouelhi","year":"2020","journal-title":"Health Qual. Life Outcome"},{"key":"10.1016\/j.heliyon.2024.e26479_bib7","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26479_bib8","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26479_bib75","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3233\/JPD-191783","article-title":"The minimal clinically relevant change of the FOG score","volume":"10","author":"Fietzek","year":"2020","journal-title":"J. Parkinsons Dis."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26479_bib47","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/mds.27769","article-title":"Abnormal involuntary movement scale in tardive dyskinesia: minimal clinically important difference","volume":"34","author":"Stacy","year":"2019","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26479_bib39","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/mds.26743","article-title":"Minimally clinically important decline in the parkinsonian variant of multiple system atrophy","volume":"31","author":"Krismer","year":"2016","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26479_bib43","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/mds.26694","article-title":"AL-108-231 Investigators. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale","volume":"31","author":"Hewer","year":"2016","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e26479_bib22","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.parkreldis.2015.09.044","article-title":"What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?","volume":"21","author":"Mestre","year":"2015","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.heliyon.2024.e26479_bib67","article-title":"Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release","volume":"2014","author":"Hauser","year":"2014","journal-title":"Parkinsons Dis"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26479_bib76","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/mds.20914","article-title":"Minimal clinically important change on the unified Parkinson's disease rating scale","volume":"21","author":"Schrag","year":"2006","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26479_bib77","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/mds.23638","article-title":"Determination of minimal clinically important change in early and advanced Parkinson's disease","volume":"26","author":"Hauser","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.heliyon.2024.e26479_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.parkreldis.2017.07.016","article-title":"Minimal clinically important difference of the modified fatigue impact scale in Parkinson's disease","volume":"43","author":"Kluger","year":"2017","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.heliyon.2024.e26479_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.parkreldis.2022.02.017","article-title":"Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine","volume":"97","author":"Hauser","year":"2022","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26479_bib58","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/mds.27660","article-title":"Minimal clinically important difference for the quality of life in essential tremor questionnaire","volume":"34","author":"Pint\u00e9r","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.heliyon.2024.e26479_bib55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.parkreldis.2018.03.002","article-title":"Minimal clinically important change in the Toronto western spasmodic torticollis rating scale","volume":"52","author":"Espay","year":"2018","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.heliyon.2024.e26479_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.07.031","article-title":"Minimal clinically important change in patients with cervical dystonia: results from the CD PROBE study","volume":"405","author":"Dashtipour","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26479_bib50","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/mds.28057","article-title":"Minimal clinically important differences for burke-fahn-marsden dystonia rating scale and 36-item short-form health survey","volume":"35","author":"Pint\u00e9r","year":"2020","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26479_bib46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1017\/S1092852920002552","article-title":"Minimal clinically important difference in AIMS score based on CGIC and PGIC in patients with tardive dyskinesia treated with deutetrabenazine","volume":"26","author":"Barkay","year":"2021","journal-title":"CNS Spectr."},{"key":"10.1016\/j.heliyon.2024.e26479_bib79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.gaitpost.2020.05.004","article-title":"Responsiveness and minimal clinically important difference of the Mini-BESTest in patients with Parkinson's disease","volume":"80","author":"Godi","year":"2020","journal-title":"Gait Posture"},{"key":"10.1016\/j.heliyon.2024.e26479_bib80","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.parkreldis.2018.11.008","article-title":"The minimum clinically important difference (MCID) for a falls intervention in Parkinson's: a delphi study","volume":"61","author":"Henderson","year":"2019","journal-title":"Parkinsonism Relat. Disorders"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26479_bib81","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mdc3.12632","article-title":"Minimal clinically important difference for UPDRS-III in daily practice","volume":"5","author":"S\u00e1nchez-Ferro","year":"2018","journal-title":"Mov Disord Clin Pract"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26479_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/mds.27303","article-title":"Are the MDS-UPDRS-based composite scores clinically applicable?","volume":"33","author":"Makkos","year":"2018","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26479_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/mds.26960","article-title":"Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale","volume":"32","author":"Horv\u00e1th","year":"2017","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2024.e26479_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000455863","article-title":"Changes in quality of life in Parkinson's disease: how large must they Be to Be relevant?","volume":"48","author":"Horv\u00e1th","year":"2017","journal-title":"Neuroepidemiology"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26479_bib16","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the Motor Examination part of MDS-UPDRS","volume":"21","author":"Horv\u00e1th","year":"2015","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.heliyon.2024.e26479_bib82","article-title":"Minimal clinically important difference on Parkinson's disease sleep scale 2nd version","volume":"2015","author":"Horv\u00e1th","year":"2015","journal-title":"Parkinsons Dis"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26479_bib34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.22240","article-title":"Determination of the longitudinal validity and minimally important difference of the 8-item Parkinson's Disease Questionnaire (PDQ-8)","volume":"24","author":"Luo","year":"2009","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26479_bib83","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1524-4733.2006.00131.x","article-title":"Longitudinal metric properties of disability rating scales for Parkinson's disease","volume":"9","author":"Martinez-Martin","year":"2006","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26479_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2003.07.003","article-title":"Distribution-based criteria for change in health-related quality of life in Parkinson's disease","volume":"57","author":"Fitzpatrick","year":"2004","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26479_bib84","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archneurol.2009.295","article-title":"The clinically important difference on the unified Parkinson's disease rating scale","volume":"67","author":"Shulman","year":"2010","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26479_bib85","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2522\/ptj.20070214","article-title":"Test-retest reliability and minimal detectable change on balance and ambulation tests, the 36-item short-form health survey, and the unified Parkinson disease rating scale in people with parkinsonism","volume":"88","author":"Steffen","year":"2008","journal-title":"Phys. Ther."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26479_bib33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ageing\/30.4.299","article-title":"Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire","volume":"30","author":"Peto","year":"2001","journal-title":"Age Ageing"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26479_bib35","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/mds.22596","article-title":"Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life","volume":"24","author":"Honig","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.heliyon.2024.e26479_bib49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.parkreldis.2021.11.016","article-title":"The minimal clinically important change in the motor section of the Burke-Fahn-Marsden Dystonia Rating Scale for generalized dystonia: results from deep brain stimulation","volume":"93","author":"Cubo","year":"2021","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.heliyon.2024.e26479_bib11","series-title":"Reference Module in Neuroscience and Biobehavioral Psychology [Internet]","article-title":"Rating scales in movement Disorders\u2606","author":"Martinez\u2013Martin","year":"2017"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26479_bib60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10654-010-9440-x","article-title":"The ongoing tyranny of statistical significance testing in biomedical research","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.heliyon.2024.e26479_bib61","unstructured":"Movement Disorder Society\u2010sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS\u2010UPDRS): Scale presentation and clinimetric testing results - Goetz - 2008 - Movement Disorders - Wiley Online Library [Internet] [cited 2023 Apr 15]. Available from: https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.22340."},{"key":"10.1016\/j.heliyon.2024.e26479_bib62","series-title":"U.S. Food and Drug Administration","year":"2020"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26479_bib63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26479_bib64","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/jns.12122","article-title":"Rasch-ionale for neurologists","volume":"20","author":"Vanhoutte","year":"2015","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26479_bib65","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1049732309331869","article-title":"Patients as partners in responsive research: methodological notions for collaborations in mixed research teams","volume":"19","author":"Abma","year":"2009","journal-title":"Qual. Health Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26479_bib66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5853\/jos.2021.02740","article-title":"The challenge of designing stroke trials that change practice: MCID vs. Sample size and pragmatism","volume":"24","author":"Goyal","year":"2022","journal-title":"J Stroke"},{"key":"10.1016\/j.heliyon.2024.e26479_bib9","article-title":"Unified Parkinson's disease rating scale","volume":"vols. 153\u201363","author":"Fahn","year":"1987"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26479_bib10","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/mds.10248","article-title":"Systematic evaluation of rating scales for impairment and disability in Parkinson's disease","volume":"17","author":"Ramaker","year":"2002","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e26479_bib12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26479_bib21","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/mds.27058","article-title":"Differential item functioning in the unified dyskinesia rating scale (UDysRS)","volume":"32","author":"Luo","year":"2017","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26479_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s00415-012-6624-1","article-title":"Expanded and independent validation of the movement disorder society-unified Parkinson's disease rating scale (MDS-UPDRS)","volume":"260","author":"Martinez-Martin","year":"2013","journal-title":"J. Neurol."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e26479_bib17","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.22341","article-title":"The unified dyskinesia rating scale: presentation and clinimetric profile","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.heliyon.2024.e26479_bib18","unstructured":"UDysRS_English_FINAL.pdf."},{"key":"10.1016\/j.heliyon.2024.e26479_bib19","unstructured":"Report Viewer | NINDS Common Data Elements [Internet] [cited 2023 Apr 8]. Available from:: https:\/\/www.commondataelements.ninds.nih.gov\/report-viewer\/137895\/Unified%20Dyskinesia%20Rating%20Scale%20(UDysRS)."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26479_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mdc3.12023","article-title":"IPMDS-sponsored scale translation Program: process, format, and clinimetric testing plan for the MDS-UPDRS and UDysRS","volume":"1","author":"Goetz","year":"2014","journal-title":"Movement Disorders Clinical Practice"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26479_bib36","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/mds.29215","article-title":"The unified multiple system atrophy rating scale: status, Critique, and recommendations","volume":"37","author":"Krismer","year":"2022","journal-title":"Mov. Disord."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e26479_bib37","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/mds.25181","article-title":"The unified multiple system atrophy rating scale: intrarater reliability","volume":"27","author":"Krismer","year":"2012","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26479_bib38","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/mds.20255","article-title":"Development and validation of the unified multiple system atrophy rating scale (UMSARS)","volume":"19","author":"Wenning","year":"2004","journal-title":"Mov. Disord."},{"issue":"Pt 6","key":"10.1016\/j.heliyon.2024.e26479_bib40","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A clinical rating scale for progressive supranuclear palsy","volume":"130","author":"Golbe","year":"2007","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26479_bib41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa","year":"2014","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26479_bib42","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26479_bib44","first-page":"781","article-title":"Abnormal involuntary movement scale (AIMS)","volume":"24","year":"1988","journal-title":"Psychopharmacol. Bull."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26479_bib48","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/mds.25579","article-title":"Dystonia rating scales: Critique and recommendations","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26479_bib51","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00702-012-0887-7","article-title":"Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy","volume":"120","author":"Jost","year":"2013","journal-title":"J. Neural. Transm."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26479_bib52","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mds.870120414","article-title":"Teaching tape for the motor section of the toronto western spasmodic torticollis scale","volume":"12","author":"Comella","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.heliyon.2024.e26479_bib53","series-title":"Clinical Review Report: AbobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada, Inc.): Indication: to Reduce the Subjective Symptoms and Objective Signs of Cervical Dystonia (Spasmodic Torticollis) in Adults [Internet]","year":"2017"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26479_bib56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.parkreldis.2005.05.009","article-title":"Quality of life in Essential Tremor Questionnaire (QUEST): development and initial validation","volume":"11","author":"Tr\u00f6ster","year":"2005","journal-title":"Parkinsonism Relat. Disorders"},{"issue":"5\u20136","key":"10.1016\/j.heliyon.2024.e26479_bib57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.18071\/isz.70.0193","article-title":"Independent validation of the quality of life in essential tremor questionnaire (QUEST)","volume":"70","author":"Kov\u00e1cs","year":"2017","journal-title":"Ideggyogyaszati Szle."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26479_bib59","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/ene.13941","article-title":"The minimum clinically important difference: which direction to take","volume":"26","author":"Draak","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26479_bib68","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.apmr.2019.12.008","article-title":"A standard method for determining the minimal clinically important difference for rehabilitation measures","volume":"101","author":"Malec","year":"2020","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26479_bib69","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/0194599819852604","article-title":"Understanding the minimal clinically important difference (MCID) of patient-reported outcome measures","volume":"161","author":"Sedaghat","year":"2019","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26479_bib70","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2020-0062","article-title":"Patient-reported outcomes in oncology clinical trials: stakeholder perspectives from the accelerating anticancer agent development and validation workshop 2019","volume":"25","author":"Bhatnagar","year":"2020","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e26479_bib71","unstructured":"Changing Patient Expectations Could Lead to More Patient-Centric Clinical Trials [Internet] Deloitte United States. [cited 2023 Apr 18]. Available from: https:\/\/www2.deloitte.com\/us\/en\/blog\/health-care-blog\/2020\/changing-patient-expectations-could-lead-to-more-patient-centric-clinical-trials.html."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26479_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002241","article-title":"Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences","volume":"3","author":"de Wit","year":"2013","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26479_bib73","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12913-017-2090-x","article-title":"Clinical trials from the patient perspective: survey in an online patient community","volume":"17","author":"DasMahapatra","year":"2017","journal-title":"BMC Health Serv. Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26479_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267030","article-title":"Patients' experiences and perspectives of patient-reported outcome measures in clinical care: a systematic review and qualitative meta-synthesis","volume":"17","author":"Carfora","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26479_bib86","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"Kinect 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am. J. Psychiatr."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26479_bib87","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI\u201098854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double\u2010blind, placebo\u2010controlled study","volume":"30","author":"O'Brien","year":"2015","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26479_bib88","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(14)70288-1","article-title":"Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial","volume":"14","author":"Poewe","year":"2015","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26479_bib89","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e26479_bib90","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1002\/mds.23317","article-title":"Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease: pramipexole ER in Early PD","volume":"25","author":"Hauser","year":"2010","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26479_bib91","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1212\/WNL.0b013e31822affb0","article-title":"Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial","volume":"77","author":"Poewe","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26479_bib92","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mds.870130112","article-title":"Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study","volume":"13","author":"Korczyn","year":"1998","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26479_bib93","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/mds.870130111","article-title":"Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study","volume":"13","author":"Rascol","year":"1998","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26479_bib94","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study","volume":"59","year":"2002","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26479_bib95","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study","volume":"62","year":"2005","journal-title":"Arch. Neurol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26479_bib96","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/mds.26597","article-title":"Randomized, controlled trial of acupuncture for fatigue in Parkinson's disease","volume":"31","author":"Kluger","year":"2016","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26479_bib97","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatr."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e26479_bib98","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024025106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024025106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:39:09Z","timestamp":1761784749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024025106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024025106"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26479","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging the gap between statistical significance and clinical relevance: A systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e26479"}}